Literature DB >> 25858146

Hepcidin regulation in prostate and its disruption in prostate cancer.

Lia Tesfay1, Kathryn A Clausen2, Jin Woo Kim3, Poornima Hegde4, Xiaohong Wang4, Lance D Miller5, Zhiyong Deng1, Nicole Blanchette1, Tara Arvedson6, Cindy K Miranti7, Jodie L Babitt8, Herbert Y Lin8, Donna M Peehl9, Frank M Torti10, Suzy V Torti11.   

Abstract

Hepcidin is a circulating peptide hormone made by the liver that is a central regulator of systemic iron uptake and recycling. Here, we report that prostate epithelial cells also synthesize hepcidin, and that synthesis and secretion of hepcidin are markedly increased in prostate cancer cells and tissue. Prostatic hepcidin functions as an autocrine hormone, decreasing cell surface ferroportin, an iron exporter, increasing intracellular iron retention, and promoting prostate cancer cell survival. Synthesis of hepcidin in prostate cancer is controlled by a unique intersection of pathways that involves BMP4/7, IL6, Wnt, and the dual BMP and Wnt antagonist, SOSTDC1. Epigenetic silencing of SOSTDC1 through methylation is increased in prostate cancer and is associated with accelerated disease progression in patients with prostate cancer. These results establish a new connection between iron metabolism and prostate cancer, and suggest that prostatic dysregulation of hepcidin contributes to prostate cancer growth and progression. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25858146      PMCID: PMC4454355          DOI: 10.1158/0008-5472.CAN-14-2465

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Authors:  Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

2.  Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.

Authors:  Xiaofeng Li; Yazhou Zhang; Heeseog Kang; Wenzhong Liu; Peng Liu; Jianghong Zhang; Stephen E Harris; Dianqing Wu
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

3.  Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.

Authors:  Iori Sakai; Hideaki Miyake; Tomoaki Terakawa; Masato Fujisawa
Journal:  Cancer Sci       Date:  2011-02-11       Impact factor: 6.716

4.  Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.

Authors:  Hiroshi Masuda; Yoshitatsu Fukabori; Katsuya Nakano; Yutaka Takezawa; Takanori CSuzuki; Hidetoshi Yamanaka
Journal:  Prostate       Date:  2003-03-01       Impact factor: 4.104

Review 5.  Iron sequestration and anemia of inflammation.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Semin Hematol       Date:  2009-10       Impact factor: 3.851

6.  Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD.

Authors:  Guillem Casanovas; Katarzyna Mleczko-Sanecka; Sandro Altamura; Matthias W Hentze; Martina U Muckenthaler
Journal:  J Mol Med (Berl)       Date:  2009-02-20       Impact factor: 4.599

Review 7.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

8.  USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney.

Authors:  Motoko Yanagita; Masako Oka; Tetsuro Watabe; Haruhisa Iguchi; Atsushi Niida; Satoru Takahashi; Tetsu Akiyama; Kohei Miyazono; Masashi Yanagisawa; Takeshi Sakurai
Journal:  Biochem Biophys Res Commun       Date:  2004-04-02       Impact factor: 3.575

9.  STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo.

Authors:  Antonello Pietrangelo; Uta Dierssen; Linda Valli; Cinzia Garuti; Agrani Rump; Elena Corradini; Matthias Ernst; Christian Klein; Christian Trautwein
Journal:  Gastroenterology       Date:  2006-10-17       Impact factor: 22.682

10.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.

Authors:  Baozhi Chen; Michael E Dodge; Wei Tang; Jianming Lu; Zhiqiang Ma; Chih-Wei Fan; Shuguang Wei; Wayne Hao; Jessica Kilgore; Noelle S Williams; Michael G Roth; James F Amatruda; Chuo Chen; Lawrence Lum
Journal:  Nat Chem Biol       Date:  2009-01-04       Impact factor: 15.040

View more
  62 in total

Review 1.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

2.  Role of hepcidin and iron metabolism in the onset of prostate cancer.

Authors:  Bin Zhao; Ruiqian Li; Gang Cheng; Zhiyao Li; Zhiping Zhang; Jun Li; Guoying Zhang; Chengwei Bi; Chen Hu; Libo Yang; Yonghong Lei; Qilin Wang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

Review 3.  Iron and Cancer.

Authors:  Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti
Journal:  Annu Rev Nutr       Date:  2018-08-21       Impact factor: 11.848

Review 4.  p53 tumor suppressor and iron homeostasis.

Authors:  Jin Zhang; Xinbin Chen
Journal:  FEBS J       Date:  2018-09-04       Impact factor: 5.542

Review 5.  Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease.

Authors:  Alexander R Bogdan; Masaki Miyazawa; Kazunori Hashimoto; Yoshiaki Tsuji
Journal:  Trends Biochem Sci       Date:  2015-12-23       Impact factor: 13.807

Review 6.  Iron and cancer: recent insights.

Authors:  David H Manz; Nicole L Blanchette; Bibbin T Paul; Frank M Torti; Suzy V Torti
Journal:  Ann N Y Acad Sci       Date:  2016-02-18       Impact factor: 5.691

7.  Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer.

Authors:  Zhiyong Deng; David H Manz; Suzy V Torti; Frank M Torti
Journal:  Antioxid Redox Signal       Date:  2017-12-11       Impact factor: 8.401

8.  SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.

Authors:  Qinyi Zhou; Jun Chen; Jialin Feng; Yanan Xu; Wenjie Zheng; Jiadong Wang
Journal:  Mol Cell Biochem       Date:  2017-05-27       Impact factor: 3.396

Review 9.  Iron and Cancer: 2020 Vision.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Cancer Res       Date:  2020-09-14       Impact factor: 12.701

Review 10.  Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology.

Authors:  Driton Vela
Journal:  Lab Invest       Date:  2017-10-23       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.